CAR-T Therapies: Rethinking Of Postmarketing Requirements And REMS Urged

 
• By Sue Sutter
Letter blocks
CAR-T postmarketing requirements may be ripe for re-evaluation. (Shutterstock)

More from Cell & Gene Therapies

More from United States